Skip to main content

Table 4 Correlations of change in selected outcome measures with drug exposure and reduction in plasma amyloid-β peptide 40 in the active arms a

From: Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease

  Semagacestat AUC Change in plasma Aβ40 AUC adjusted for Aβ40 Aβ40 adjusted for AUC
  r n P r n P r n P r n P
Change in uric acid at week 76 −0.151 320 0.007 0.011 263 0.857 −0.149 260 0.016 0.071 260 0.255
Change in albumin at week 76 −0.14 320 0.012 −0.131 263 0.033 −0.037 260 0.548 −0.107 260 0.084
Gastrointestinal symptoms 0.015 943 0.654 0.099 507 0.025 −0.004 501 0.933 0.094 501 0.034
Skin disorder incidence 0.016 943 0.627 0.083 507 0.062 −0.048 501 0.279 0.096 501 0.031
Skin cancer incidence −0.012 943 0.71 0.075 507 0.091 −0.039 501 0.389 0.084 501 0.059
Infection incidence 0.136 943 <0.001 0.072 507 0.101 0.068 501 0.129 0.042 501 0.344
Annualized change in FDG SUVR 0.22 74 0.06 <0.001 48 0.998 0.357 48 0.010 −0.134 48 0.364
Annualized change in ventricular volume 0.003 139 0.97 0.242 91 0.021 −0.109 91 0.302 0.264 91 0.010
Annualized change in right hippocampal volume −0.064 130 0.472 −0.264 86 0.014 −0.039 86 0.719 −0.222 86 0.038
Annualized change in left hippocampal volume −0.109 130 0.216 −0.036 86 0.74 −0.167 86 0.123 0.043 86 0.697
Annualized change in AV45 SUVR 0.133 40 0.414 0.316 27 0.109 −0.079 27 0.697 0.324 27 0.093
Annualized change in ADASCog11 −0.012 938 0.707 0.037 505 0.403 −0.080 499 0.074 0.060 499 0.177
Annualized change in MMSE 0.038 618 0.351 −0.019 496 0.678 0.057 490 0.211 −0.037 490 0.414
Annualized change in p-tau 0.02 37 0.909 −0.124 33 0.491 0.101 33 0.578 −0.154 33 0.395
Annualized change in total tau 0.07 35 0.691 0.003 31 0.986 −0.017 31 0.930 0.010 31 0.957
Annualized change in CSF Aβ42 −0.13 37 0.443 0.152 33 0.399 −0.103 33 0.571 0.179 33 0.318
  1. aAβ40, Amyloid-β peptide 40; Aβ42, Amyloid-β peptide 42; ADAScog11, Alzheimer’s Disease Assessment Scale Cognitive Subscale, 11-item version; AUC, Area under the concentration curve; AV45, Florbetapir; CSF, Cerebrospinal fluid; FDG-PET, Fludeoxyglucose positron emission tomography; MMSE, Mini Mental State Examination; p-tau, Phosphorylated tau; SUVR, Standard uptake value ratio.